Human immunodeficiency virus type 1 envelope glycoprotein complex (HIV-1 Env)

The **Human immunodeficiency virus type 1 envelope glycoprotein complex (HIV-1 Env)** is an oligomeric trimer composed of gp120 and gp41 subunits, derived from the precursor gp160, and mediates viral entry into host cells[1][2][3][5]. Gp120 binds the host cell receptor CD4 and a chemokine co-receptor (often CCR5 or CXCR4), triggering conformational changes that enable gp41 to promote fusion between the viral and host plasma membranes[2][9]. Env is heavily glycosylated and highly variable, facilitating evasion of neutralizing antibodies[7]. Therapeutic agents targeting Env include entry inhibitors such as enfuvirtide and several broadly neutralizing monoclonal antibodies[5]. Due to its essential role in HIV infection and its surface accessibility, Env is the principal target for neutralizing antibodies and a major focus in HIV vaccine and therapeutic development[3][5]. In addition, host cell proteins such as MHC molecules and integrins can be incorporated into the viral envelope during budding, impacting infectivity and immune recognition[8]. --- **Note:** - This entry is marked **is_incorrect: true** because the target combines *multiple distinct entities* (HIV-1 Env proteins plus “associated host cell proteins”), which is not standard nomenclature and confounds retrieval and classification. Structurally, *HIV-1 envelope glycoprotein* is the canonical singular target, while “associated host cell proteins” should be handled as separate, specific entries. - If you need information for specific *host cell proteins* associated with HIV-1 entry (for example, CD4, CCR5, or CXCR4), request them individually for structured data.

Other names

HIV-1 EnvHIV envelope proteinenvelope glycoprotein gp120-gp41 complexHIV-1 spike glycoproteingp120gp41

Inhibition of gp41-mediated fusion; Blockade of gp120-CD4 interaction; Allosteric inhibition of conformational change; Antibody neutralization of Env